APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intranasal Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Intranasal Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchIntranasal Vaccine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Intranasal Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Intranasal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intranasal Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Intranasal Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Intranasal Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Intranasal Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intranasal Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intranasal Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Intranasal Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Intranasal Vaccine market include Abbott, Beijing Wantai Biopharmaceutical Co., Ltd., Sanofi, GlaxoSmithKline, Changchun Baike Company, AstraZeneca, Serum Institute of India, PharmaJet and Crossject and INJEX Pharma GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intranasal Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intranasal Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intranasal Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intranasal Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Intranasal Vaccine Segment by Company

Abbott

Beijing Wantai Biopharmaceutical Co., Ltd.

Sanofi

GlaxoSmithKline

Changchun Baike Company

AstraZeneca

Serum Institute of India

PharmaJet and Crossject

INJEX Pharma GmbH

BioDiem

Bharat Biotech

Antares Pharma

Intranasal Vaccine Segment by Type

Flu Vaccine

COVID-19 Vaccines

Intranasal Vaccine Segment by Application

Hospital

Clinic

Intranasal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Intranasal Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Intranasal Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Intranasal Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Intranasal Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intranasal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intranasal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intranasal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intranasal Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intranasal Vaccine industry.

Chapter 3: Detailed analysis of Intranasal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Intranasal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Intranasal Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Intranasal Vaccine Industry Trends Table 2. Intranasal Vaccine Industry Drivers Table 3. Intranasal Vaccine Industry Opportunities and Challenges Table 4. Intranasal Vaccine Industry Restraints Table 5. Global Intranasal Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Intranasal Vaccine Revenue Share by Company (2021-2026) Table 7. Global Intranasal Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Intranasal Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Intranasal Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Intranasal Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Intranasal Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Intranasal Vaccine Company, Product Type & Application Table 13. Global Intranasal Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Intranasal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Flu Vaccine Table 18. Significant Companies of COVID-19 Vaccines Table 19. Global Intranasal Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Intranasal Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Intranasal Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Intranasal Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Intranasal Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Intranasal Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Intranasal Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Intranasal Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Intranasal Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Intranasal Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Intranasal Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Intranasal Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Intranasal Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Intranasal Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Intranasal Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Intranasal Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Intranasal Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Intranasal Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Intranasal Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Intranasal Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Intranasal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Intranasal Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Intranasal Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Intranasal Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global Intranasal Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Intranasal Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Intranasal Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Intranasal Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Intranasal Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Intranasal Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Intranasal Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Intranasal Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Intranasal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Intranasal Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Intranasal Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global Intranasal Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Intranasal Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Intranasal Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Intranasal Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Intranasal Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Intranasal Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Intranasal Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Abbott Company Information Table 64. Abbott Business Overview Table 65. Abbott Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Abbott Intranasal Vaccine Product Portfolio Table 67. Abbott Recent Development Table 68. Beijing Wantai Biopharmaceutical Co., Ltd. Company Information Table 69. Beijing Wantai Biopharmaceutical Co., Ltd. Business Overview Table 70. Beijing Wantai Biopharmaceutical Co., Ltd. Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Beijing Wantai Biopharmaceutical Co., Ltd. Intranasal Vaccine Product Portfolio Table 72. Beijing Wantai Biopharmaceutical Co., Ltd. Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sanofi Intranasal Vaccine Product Portfolio Table 77. Sanofi Recent Development Table 78. GlaxoSmithKline Company Information Table 79. GlaxoSmithKline Business Overview Table 80. GlaxoSmithKline Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. GlaxoSmithKline Intranasal Vaccine Product Portfolio Table 82. GlaxoSmithKline Recent Development Table 83. Changchun Baike Company Company Information Table 84. Changchun Baike Company Business Overview Table 85. Changchun Baike Company Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Changchun Baike Company Intranasal Vaccine Product Portfolio Table 87. Changchun Baike Company Recent Development Table 88. AstraZeneca Company Information Table 89. AstraZeneca Business Overview Table 90. AstraZeneca Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. AstraZeneca Intranasal Vaccine Product Portfolio Table 92. AstraZeneca Recent Development Table 93. Serum Institute of India Company Information Table 94. Serum Institute of India Business Overview Table 95. Serum Institute of India Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Serum Institute of India Intranasal Vaccine Product Portfolio Table 97. Serum Institute of India Recent Development Table 98. PharmaJet and Crossject Company Information Table 99. PharmaJet and Crossject Business Overview Table 100. PharmaJet and Crossject Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. PharmaJet and Crossject Intranasal Vaccine Product Portfolio Table 102. PharmaJet and Crossject Recent Development Table 103. INJEX Pharma GmbH Company Information Table 104. INJEX Pharma GmbH Business Overview Table 105. INJEX Pharma GmbH Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. INJEX Pharma GmbH Intranasal Vaccine Product Portfolio Table 107. INJEX Pharma GmbH Recent Development Table 108. BioDiem Company Information Table 109. BioDiem Business Overview Table 110. BioDiem Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. BioDiem Intranasal Vaccine Product Portfolio Table 112. BioDiem Recent Development Table 113. Bharat Biotech Company Information Table 114. Bharat Biotech Business Overview Table 115. Bharat Biotech Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Bharat Biotech Intranasal Vaccine Product Portfolio Table 117. Bharat Biotech Recent Development Table 118. Antares Pharma Company Information Table 119. Antares Pharma Business Overview Table 120. Antares Pharma Intranasal Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Antares Pharma Intranasal Vaccine Product Portfolio Table 122. Antares Pharma Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Intranasal Vaccine Distributors List Table 126. Intranasal Vaccine Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Intranasal Vaccine Product Image Figure 2. Global Intranasal Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intranasal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Intranasal Vaccine Sales (2021-2032) & (k units) Figure 5. Global Intranasal Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Intranasal Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Flu Vaccine Image Figure 10. COVID-19 Vaccines Image Figure 11. Global Intranasal Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Intranasal Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Intranasal Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Intranasal Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Intranasal Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Intranasal Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Intranasal Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Intranasal Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Intranasal Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Intranasal Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Intranasal Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Intranasal Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Intranasal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Intranasal Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Intranasal Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Intranasal Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Intranasal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Intranasal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Intranasal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Intranasal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Intranasal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Intranasal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Intranasal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Intranasal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Intranasal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Intranasal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Intranasal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Intranasal Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Intranasal Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Flu Vaccine
  • COVID-19 Vaccines
Applications
  • Hospital
  • Clinic
Companies covered
  • Abbott
  • Beijing Wantai Biopharmaceutical Co., Ltd.
  • Sanofi
  • GlaxoSmithKline
  • Changchun Baike Company
  • AstraZeneca
  • Serum Institute of India
  • PharmaJet and Crossject
  • INJEX Pharma GmbH
  • BioDiem
  • Bharat Biotech
  • Antares Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Intranasal Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Intranasal Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Intranasal Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Intranasal Vaccine Market Dynamics
  1. 2.1 Intranasal Vaccine Industry Trends
  2. 2.2 Intranasal Vaccine Industry Drivers
  3. 2.3 Intranasal Vaccine Industry Opportunities and Challenges
  4. 2.4 Intranasal Vaccine Industry Restraints
3 Intranasal Vaccine Market by Company
  1. 3.1 Global Intranasal Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Intranasal Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Intranasal Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Intranasal Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Intranasal Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Intranasal Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Intranasal Vaccine Company Product Type and Application
  8. 3.8 Global Intranasal Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Intranasal Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Intranasal Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Intranasal Vaccine Market by Type
  1. 4.1 Intranasal Vaccine Type Introduction
  2. 4.1.1 Flu Vaccine
  3. 4.1.2 COVID-19 Vaccines
  4. 4.2 Global Intranasal Vaccine Sales Volume by Type
  5. 4.2.1 Global Intranasal Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Intranasal Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Intranasal Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Intranasal Vaccine Sales Value by Type
  9. 4.3.1 Global Intranasal Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Intranasal Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Intranasal Vaccine Sales Value Share by Type (2021-2032)
5 Intranasal Vaccine Market by Application
  1. 5.1 Intranasal Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Intranasal Vaccine Sales Volume by Application
  5. 5.2.1 Global Intranasal Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Intranasal Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Intranasal Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Intranasal Vaccine Sales Value by Application
  9. 5.3.1 Global Intranasal Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Intranasal Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Intranasal Vaccine Sales Value Share by Application (2021-2032)
6 Intranasal Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Intranasal Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intranasal Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Intranasal Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Intranasal Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Intranasal Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Intranasal Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Intranasal Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Intranasal Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Intranasal Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Intranasal Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Intranasal Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Intranasal Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Intranasal Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Intranasal Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Intranasal Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Intranasal Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Intranasal Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Intranasal Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Intranasal Vaccine Sales Value Share by Country, 2025 VS 2032
7 Intranasal Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Intranasal Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Intranasal Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Intranasal Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Intranasal Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Intranasal Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Intranasal Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Intranasal Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Intranasal Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Intranasal Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Intranasal Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Intranasal Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Intranasal Vaccine Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Beijing Wantai Biopharmaceutical Co., Ltd.
  8. 8.2.1 Beijing Wantai Biopharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Beijing Wantai Biopharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Beijing Wantai Biopharmaceutical Co., Ltd. Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beijing Wantai Biopharmaceutical Co., Ltd. Intranasal Vaccine Product Portfolio
  12. 8.2.5 Beijing Wantai Biopharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Intranasal Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Intranasal Vaccine Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Changchun Baike Company
  26. 8.5.1 Changchun Baike Company Company Information
  27. 8.5.2 Changchun Baike Company Business Overview
  28. 8.5.3 Changchun Baike Company Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Changchun Baike Company Intranasal Vaccine Product Portfolio
  30. 8.5.5 Changchun Baike Company Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Intranasal Vaccine Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Serum Institute of India
  38. 8.7.1 Serum Institute of India Company Information
  39. 8.7.2 Serum Institute of India Business Overview
  40. 8.7.3 Serum Institute of India Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Intranasal Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Recent Developments
  43. 8.8 PharmaJet and Crossject
  44. 8.8.1 PharmaJet and Crossject Company Information
  45. 8.8.2 PharmaJet and Crossject Business Overview
  46. 8.8.3 PharmaJet and Crossject Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 PharmaJet and Crossject Intranasal Vaccine Product Portfolio
  48. 8.8.5 PharmaJet and Crossject Recent Developments
  49. 8.9 INJEX Pharma GmbH
  50. 8.9.1 INJEX Pharma GmbH Company Information
  51. 8.9.2 INJEX Pharma GmbH Business Overview
  52. 8.9.3 INJEX Pharma GmbH Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 INJEX Pharma GmbH Intranasal Vaccine Product Portfolio
  54. 8.9.5 INJEX Pharma GmbH Recent Developments
  55. 8.10 BioDiem
  56. 8.10.1 BioDiem Company Information
  57. 8.10.2 BioDiem Business Overview
  58. 8.10.3 BioDiem Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 BioDiem Intranasal Vaccine Product Portfolio
  60. 8.10.5 BioDiem Recent Developments
  61. 8.11 Bharat Biotech
  62. 8.11.1 Bharat Biotech Company Information
  63. 8.11.2 Bharat Biotech Business Overview
  64. 8.11.3 Bharat Biotech Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bharat Biotech Intranasal Vaccine Product Portfolio
  66. 8.11.5 Bharat Biotech Recent Developments
  67. 8.12 Antares Pharma
  68. 8.12.1 Antares Pharma Company Information
  69. 8.12.2 Antares Pharma Business Overview
  70. 8.12.3 Antares Pharma Intranasal Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Antares Pharma Intranasal Vaccine Product Portfolio
  72. 8.12.5 Antares Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intranasal Vaccine Value Chain Analysis
  2. 9.1.1 Intranasal Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intranasal Vaccine Sales Mode & Process
  6. 9.2 Intranasal Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intranasal Vaccine Distributors
  9. 9.2.3 Intranasal Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst